Press release
Severe Asthma Clinical Trial Pipeline Analysis: 30+ Key Companies Shaping the Future of Severe Asthma Therapeutics | DelveInsight
DelveInsight's Severe Asthma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Severe Asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Severe Asthma pipeline domain.Key takeaways from the Severe Asthma Clinical Trial Landscape Report
• DelveInsight's Severe Asthma pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Severe Asthma treatment.
• Key Severe Asthma companies such as AstraZeneca, Sanofi, Regeneron Pharmaceuticals, GSK, Teva Pharmaceutical Industries, Amgen, Roche, Novartis, and others
• Promising Severe Asthma pipeline therapies in various stages of development include Tezepelumab, Dupilumab, Benralizumab, Astegolimab, and others
Request a sample and discover the recent advances in Severe Asthma treatment drugs at: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Severe Asthma?
Severe Asthma is a chronic form of asthma characterized by persistent symptoms, frequent exacerbations, and reduced lung function despite high-dose inhaled corticosteroids and additional controller therapies. It is associated with airway inflammation, bronchial hyperresponsiveness, and airflow limitation. The symptoms include breathlessness, wheezing, chest tightness, and coughing. The treatment involves inhaled therapies, biologics, and systemic corticosteroids. The causes are associated with immune dysregulation and environmental triggers. The diagnosis is based on clinical examination, pulmonary function tests, biomarker analysis, and patient history.
Emerging Severe Asthma Drug Profiles
Tezepelumab: AstraZeneca/Amgen
Tezepelumab is a first-in-class thymic stromal lymphopoietin (TSLP) inhibitor designed to block upstream inflammatory pathways involved in asthma pathogenesis. Its active mechanism targets epithelial cytokines, reducing airway inflammation and exacerbation rates. The therapy is administered subcutaneously and has demonstrated efficacy across a broad population of severe asthma patients.
Dupilumab: Sanofi/Regeneron Pharmaceuticals
Dupilumab is a monoclonal antibody targeting IL-4 and IL-13 signaling pathways, key drivers of type 2 inflammation in severe asthma. It is administered via subcutaneous injection and is being evaluated across multiple clinical studies for its effectiveness in reducing exacerbations and improving lung function.
Learn more about the novel and emerging Severe Asthma pipeline therapies at: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the Severe Asthma Clinical Trial Landscape
• In March 2026, AstraZeneca announced ongoing clinical progress with Tezepelumab in Severe Asthma, highlighting continued evaluation across patient populations.
• In February 2025, Sanofi and Regeneron Pharmaceuticals reported continued clinical development of Dupilumab for Severe Asthma, focusing on long-term outcomes and efficacy across diverse patient groups.
• In April 2026, GSK reported continued advancement of Benralizumab in patients with Severe Asthma, highlighting encouraging efficacy signals in ongoing studies.
• In March 2026, Roche announced ongoing clinical development activities for its Severe Asthma pipeline candidates, focusing on advancing targeted therapies across early and mid-stage trials.
• In February 2026, Novartis provided updates on Severe Asthma pipeline therapies, indicating continued enrollment and evaluation in clinical trials.
Scope of the Severe Asthma Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Inhalation
• Therapeutics Assessment By Molecule Type: Recombinant proteins, Small molecule, Monoclonal antibody, Peptide, Gene Therapy
• Key Severe Asthma Companies: AstraZeneca, Sanofi, Regeneron Pharmaceuticals, GSK, Teva Pharmaceutical Industries, Amgen, Roche, Novartis, and others
• Key Severe Asthma Pipeline Therapies: Tezepelumab, Dupilumab, Benralizumab, Astegolimab, and others
Dive deep into rich insights for new drugs for Severe Asthma treatment, visit https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Severe Asthma Pipeline Report Introduction
2. Severe Asthma Pipeline Report Executive Summary
3. Severe Asthma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Severe Asthma Pipeline Therapeutics
6. Severe Asthma Pipeline: Late Stage Products (Pre-registration)
7. Severe Asthma Pipeline: Late Stage Products (Phase III)
8. Severe Asthma Pipeline: Mid Stage Products (Phase II)
9. Severe Asthma Pipeline: Early Stage Products (Phase I)
10. Severe Asthma Pipeline Therapeutics Assessment
11. Inactive Products in the Severe Asthma Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Severe Asthma Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the Severe Asthma pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight ?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Asthma Clinical Trial Pipeline Analysis: 30+ Key Companies Shaping the Future of Severe Asthma Therapeutics | DelveInsight here
News-ID: 4500582 • Views: …
More Releases from DelveIinsight Business Research
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Analysis: 40+ Key Co …
DelveInsight's Acute Respiratory Distress Syndrome (ARDS) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Acute Respiratory Distress Syndrome (ARDS) therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Respiratory Distress Syndrome (ARDS) pipeline domain.
Key takeaways from the Acute Respiratory Distress Syndrome (ARDS) Clinical Trial Landscape Report
• DelveInsight's Acute Respiratory Distress Syndrome…
Systemic Lupus Erythematosus Clinical Trial Pipeline Analysis: 120+ Key Companie …
DelveInsight's Systemic Lupus Erythematosus (SLE) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline SLE therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the SLE pipeline domain.
Key takeaways from the SLE Clinical Trial Landscape Report
• DelveInsight's SLE pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies…
Chronic Rhinosinusitis with Nasal Polyps Market Size in the 7MM is Projected to …
The market dynamics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) therapies is witnessing significant growth driven by the rising diagnosed prevalent patient pool, increasing awareness of persistent sinonasal symptoms, improving diagnosis rates, and expanding adoption of biologic therapies. Growing demand for targeted therapies with durable disease control, advancements in endoscopic interventions, and increasing use of corticosteroids and monoclonal antibodies are further supporting market expansion. Additionally, the launch of emerging therapies…
Charcot-Marie-Tooth Market Size in the 7MM is Projected to Enhance at a Signific …
The market dynamics for Charcot-Marie-Tooth (CMT) therapies is witnessing significant growth driven by the rising diagnosed patient population, increasing awareness of inherited neuropathies, expanding access to genetic testing, and growing demand for disease-modifying treatment options. Improved disease recognition, better supportive care pathways, and increasing clinical research activity are further supporting market expansion. Additionally, the launch of emerging therapies such as Govorestat (Applied Therapeutics), Ignaseclant/NMD670 (NMD Pharma), IFB-088 (InFlectis BioSciences), and…
More Releases for Severe
Painkillers for particularly severe back pain
Not all back pain is mild. While many complaints subside after a few days with rest and mild painkillers, there are situations in which the intensity is significantly higher. Those affected describe stabbing, deep-seated or radiating pain that significantly restricts even simple movements.
Particularly in cases of disc problems, severe muscle spasms or nerve root irritation, the strain can be so severe that targeted pain therapy is necessary.
The aim is…
PMS or PMDD? Understanding Severe Premenstrual Mood Changes
Many women notice mood shifts before their period. They may feel more emotional, tired, or irritable. This is often labeled PMS. For some, symptoms are mild and manageable. For others, they are intense and disruptive.
When mood changes become severe, especially when they affect work, school, or relationships, it may be something more serious. That condition is called PMDD.
Understanding the difference between typical premenstrual symptoms and a psychiatric condition can help…
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's analysis highlights that several key companies are actively…
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and…
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage
The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS).
The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
